In this setting, the more recent pharmacological options for HF, such as the angiotensin receptor–neprilysin inhibitors or the SGLT2 inhibitors, have shown promising results in improving the positive remodelling of the left ventricle and reducing the ventricular arrhythmic burden in HF patients17, 18 and should not be discontinued even after improvement in EF.19 The gene discussed is MME; the disease is hydrops fetalis.